What Happened
Biosynthesis Company To Bolster Domestic Pharmaceutical Production
Antheia, a biosynthesis company, has secured a conditional commitment of up to $80 million in a long-term loan from the Office of Strategic Capital under the US Department of Defense. The funding aims to support the onshoring of production for critical pharmaceutical ingredients, reducing the country’s reliance on foreign suppliers. According to Antheia, the US currently imports 90% of its key starting materials and active pharmaceutical ingredients, creating vulnerabilities to drug shortages and supply chain disruptions. This development was first reported by Homeland Preparedness News.